Tandem Diabetes Secures FDA Approval for Mobi Android Version, Shares Surge

Tandem Diabetes Care received a significant boost on November 11, 2025, as its stock surged nearly 20% following the FDA approval for the Android version of its Mobi insulin pump app. This approval marks a pivotal step in enhancing diabetes management through mobile technology. With the integration of Android compatibility, Tandem aims to improve user accessibility and convenience, setting a new standard in diabetes care technology.